{"id":"NCT03877224","sponsor":"AstraZeneca","briefTitle":"DETERMINE-preserved - Dapagliflozin Effect on Exercise Capacity Using a 6-minute Walk Test in Patients With Heart Failure With Preserved Ejection Fraction","officialTitle":"International, Multicentre, Parallel-group, Randomised, Double-blind, Placebo-controlled, Phase III Study Evaluating the Effect of Dapagliflozin on Exercise Capacity in Heart Failure Patients With Preserved Ejection Fraction","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2019-04-04","primaryCompletion":"2020-07-09","completion":"2020-07-09","firstPosted":"2019-03-15","resultsPosted":"2021-11-17","lastUpdate":"2021-11-17"},"enrollment":504,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"TRIPLE","primaryPurpose":"TREATMENT"},"conditions":["Heart Failure With Preserved Ejection Fraction (HFpEF)"],"interventions":[{"type":"DRUG","name":"Dapagliflozin","otherNames":[]},{"type":"OTHER","name":"Placebo","otherNames":[]}],"arms":[{"label":"Dapagliflozin","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"International, Multicentre, Parallel-group, Randomised, Double-blind, Placebo-controlled, Phase III Study Evaluating the effect of Dapagliflozin on Exercise Capacity in Heart Failure Patients with Preserved Ejection Fraction (HFpEF)","primaryOutcome":{"measure":"Change From Baseline in Kansas-City Cardiomyopathy Questionnaire-Total Symptom Score (KCCQ-TSS) at Week 16 (Higher Scores Represent Less HF Symptom Frequency and Burden)","timeFrame":"At baseline and at week 16 or death before week 16","effectByArm":[{"arm":"Dapa 10mg","deltaMin":5.21,"sd":null},{"arm":"Placebo","deltaMin":1.04,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"0.07905"}]},"eligibility":{"minAge":"40 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":7,"exclusionCount":13},"locations":{"siteCount":101,"countries":["United States","Argentina","Brazil","Bulgaria","Canada","Denmark","Italy","Japan","Slovakia","South Africa","South Korea","Sweden"]},"refs":{"pmids":["39212948","38059368"],"seeAlso":["https://filehosting-v2.pharmacm.com/api/Attachment/Download?tenantId=80217111&amp;parentIdentifier=D169EC00001&amp;attachmentIdentifier=45f3cba7-8c50-41b7-a77f-d2639dc48d00&amp;fileName=d169ec00001-csp-v3_Redacted.pdf&amp;versionIdentifier=","https://filehosting-v2.pharmacm.com/api/Attachment/Download?tenantId=80217111&amp;parentIdentifier=D169EC00001&amp;attachmentIdentifier=3c3d4d25-5187-4fc0-a496-5c4d63033c96&amp;fileName=d169ec00001-sap-ed-4_Redacted.pdf&amp;versionIdentifier=","https://filehosting-v2.pharmacm.com/api/Attachment/Download?tenantId=80217111&amp;parentIdentifier=D169EC00001&amp;attachmentIdentifier=c16f75c8-34a0-4fe2-9cac-d88d8673f9d9&amp;fileName=d169ec00001-study-synopsis_Redacted.pdf&amp;versionIdentifier="]},"adverseEventsSummary":{"seriousAny":{"events":26,"n":252},"commonTop":[]}}